Group 1 - The core viewpoint of the articles highlights the renewed activity in the innovative drug sector, driven by supportive government policies and recent approvals of innovative drugs in the domestic market [1][2] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific measures across five areas [1] - The introduction of a commercial health insurance directory for innovative drugs aims to include high-value, clinically significant drugs that are not yet part of the basic medical insurance list, indicating a shift towards multi-layered medical insurance systems [1] Group 2 - East China Securities emphasizes the strong policy support for innovative drug development, which is expected to lead to significant growth in the market as new drugs are approved and commercial insurance directories are established [2] - The successful international approval of domestic innovative drugs, such as the approval of Shuwotini by Dize Pharmaceutical in the U.S., showcases the international competitiveness of local innovative drugs [2] - The innovative drug sector is identified as a core investment theme within the biopharmaceutical industry, with recommendations to explore investment opportunities in related segments such as medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2]

Market Overview - The pharmaceutical sector experienced a significant surge on July 10, with stocks such as Seer Medical, Lianhuan Pharmaceutical, and Kangchen Pharmaceutical hitting the daily limit [1] - Seer Medical recorded a price of 25.61 with a rise of 10.01%, Lianhuan Pharmaceutical reached 13.62 with a 10.02% increase, and Kangchen Pharmaceutical was at 40.68 with a 10.01% gain [2] Key Events - Merck, a major U.S. pharmaceutical company, announced its intention to acquire UK-based Verona Pharma for approximately $10 billion to enhance its product line for chronic obstructive pulmonary disease (COPD) [3] - Former President Trump threatened to impose a 200% tariff on pharmaceuticals, although this may not take effect immediately, allowing pharmaceutical companies a one-year buffer [3] - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, including 16 initiatives to enhance support for R&D and encourage clinical application [3] Institutional Insights - The trend of Chinese innovative drugs entering international markets is expected to grow over the next 3-5 years, driven by improved innovation capabilities and profitability of Chinese pharmaceutical companies, which will enhance industry valuation levels [4] - The upstream raw material drug sector has seen a valuation adjustment, now positioned at relatively low levels, with the commercialization of GLP-1 products expected to drive growth in upstream peptide raw materials [4] - As the mid-year reporting period approaches, performance metrics will become a focal point for the market, with expectations for continued improvement in innovative drugs and their supply chains [4]

Group 1 - The innovative drug concept stocks are experiencing significant activity, with companies like Seer Medical (603716) and Kangchen Pharmaceutical (603590) hitting the daily limit up [1] - Haikang Pharmaceutical (002653) has seen an increase of over 7%, indicating strong market interest [1] - Other companies such as Xianda Co., Ltd. (603086), Warner Pharmaceuticals, and Microchip Biotech are also witnessing upward movements in their stock prices [1]

Core Viewpoint - Haisco Pharmaceutical Group Co., Ltd. is applying for a specific issuance of A-shares, which is expected to enhance its capital strength and support the development of innovative drugs, thereby improving its market position and long-term sustainability [1][24]. Group 1: Issuance Details - The lead underwriter for the issuance is CITIC Securities Co., Ltd. [2] - The project representatives from CITIC Securities include Shen Ziquan and Wang Qi, with a team of other members involved in the underwriting process [2][3]. - The issuance aims to raise funds for new drug research and to supplement working capital, which is aligned with the company's strategic development goals [24]. Group 2: Company Information - Haisco Pharmaceutical Group Co., Ltd. has a registered capital of 1,119,917,970 RMB and is listed on the Shenzhen Stock Exchange under the stock code 002653 [4]. - The company specializes in the sale of chemical products, medical research, and development, among other activities [4]. - As of March 31, 2025, the major shareholders include Wang Junmin, who holds 35.68% of the shares, and his spouse, Shen Ping, who holds 4.43% [16][17]. Group 3: Financial Performance - The company reported an operating income of 89,201.30 million RMB for the year 2024, with a net profit attributable to shareholders of 4,661.19 million RMB [16]. - The comprehensive gross margin for 2024 was 70.29%, indicating a slight decrease from the previous year [16]. - The total assets of the company as of March 31, 2025, amounted to 692,474.32 million RMB, with total liabilities of 281,085.39 million RMB [16]. Group 4: Corporate Governance - The board of directors approved the issuance plan on February 27, 2025, and further discussions were held on April 3, 2025, confirming the company's readiness for the issuance [24]. - The company has undergone necessary due diligence and compliance checks as per regulatory requirements, ensuring that the issuance aligns with legal and industry standards [23][24].

Core Viewpoint - The legal opinion letter from Beijing Zhonglun Law Firm confirms that Haisco Pharmaceutical Group Co., Ltd. has obtained the necessary internal approvals and authorizations for its upcoming issuance of A-shares to specific investors, pending review by the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [1][4][25]. Group 1: Approval and Authorization - The shareholders' meeting of the issuer has legally approved the issuance and authorized the board of directors to handle related matters [4]. - The issuer has obtained all necessary internal approvals and authorizations for the issuance of shares [4][25]. Group 2: Subject Qualification - The issuer is a joint-stock company established in accordance with the Company Law and has been registered since August 23, 2010 [4]. - The issuer is currently in good standing and possesses the qualifications required for the issuance of shares [4]. Group 3: Substantial Conditions for Issuance - The issuance complies with the conditions set forth in the Company Law and Securities Law, as well as relevant regulations [4][11]. Group 4: Share Capital Evolution - The issuer's total share capital has undergone several changes since its initial public offering, with the current total share capital amounting to 1,119,917,970 shares as of the latest issuance [5][8][17]. Group 5: Major Shareholders and Control - As of March 31, 2025, major shareholders include Wang Junmin, Fan Xiulian, and Zheng Wei, with Wang Junmin holding 35.68% of the total shares [9][10]. - Wang Junmin is identified as the actual controller of the issuer, with significant influence over strategic decisions [9][10]. Group 6: Independence of the Issuer - The issuer maintains independence in its assets, personnel, finance, and operations, ensuring its ability to operate continuously in the market [10]. Group 7: Business Operations - The issuer's main business involves the research, production, and sale of pharmaceuticals, with operations running normally and no significant changes in business nature [11]. Group 8: Related Transactions and Competition - The issuer has established clear procedures for related transactions, ensuring fairness and compliance with regulations, and there are no significant competitive issues with related parties [12][13]. Group 9: Major Assets - As of March 31, 2025, the issuer owns various assets, including land use rights, trademarks, and patents, with no disputes affecting the issuance [17][19]. Group 10: Fund Utilization - The total amount to be raised from the issuance is not to exceed 1,365.2567 million yuan, which will be used for new drug research and development projects and to supplement working capital [21][23].

中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行A股股票 之 发行保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路8号卓越时代广场（二期）北座 二〇二五年六月 | 目 | 录 | 1 | | --- | --- | --- | | 声 | 明 | 2 | | 第一节 | | 本次证券发行基本情况 3 | | | | 一、保荐人名称 3 | | | | 二、项目保荐代表人、协办人及其它项目组成员情况 3 | | | | 三、发行人情况 3 | | | | 四、保荐人与发行人存在的关联关系 13 | | | | 五、保荐人内部审核程序和内核意见 14 | | 第二节 | | 保荐人承诺事项 16 | | 第三节 | | 保荐人对本次证券发行上市的保荐结论 17 | | | | 一、对本次证券发行的推荐结论 17 | | | | 二、本次证券发行决策程序 17 | | | | 三、发行人符合《公司法》及《证券法》规定的相关条件 18 | | | | 四、发行人符合《注册管理办法》规定的相关条件 18 | | | | 五、本次发行符合《<注册管理办法>第九条、第十条、第十一条、第十三 | ...

北京市中伦律师事务所 关于海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票的 法律意见书 致：海思科医药集团股份有限公司 北京市中伦律师事务所（简称"本所"）作为海思科医药集团股份有限公司 （简称"公司""发行人"或"海思科"）申请向特定对象发行人民币普通股（A 股）股票（简称"本次发行"）相关事宜聘请的专项法律顾问，现为发行人申请 本次发行出具法律意见书。 根据本所与公司签订的《法律顾问聘请协议》，本所律师对公司本次发行的 有关文件资料进行了审查，并获授权出具法律意见书和律师工作报告。 发行人已向本所作出保证：发行人已向本所提供了本所认为出具法律意见书 所必需的真实的原始材料、副本材料或复制件，公司向本所提供的文件并无遗漏， 所有文件上的签名、印章均是真实的，所有副本材料或复制件均与原件一致。 二〇二五年六月 北京市中伦律师事务所 关于海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票的 法律意见书 对出具本法律意见书至关重要而又无法得到独立证据支持的事实，本所依赖 有关政府主管部门或其他有关单位出具的证明文件，出具法律意见。 本所律师依据我国现行有效的或发行人行为、有 ...

海思科医药集团股份有限公司 | 信永中和 | | --- | | ShineWing | 六计师事务所 | 北京市东城区朝阳门北大街 审计报告 XYZH/2025CDAA3B0092 海思科医药集团股份有限公司 2024 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-6 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-105 | 6-1-1 海思科医药集团股份有限公司全体股东: 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计 师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册 会计师职业道德守则,我们独立于海思科公司,并履行了职业道德方面的其他责任。我 们相信,我们获取的审计证据是充分、适当的,为发表审计意见提供了基础。 三 ...

中信证券股份有限公司 关于 海思科医药集团股份有限公司 向特定对象发行 A 股股票 之 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年六月 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 声 明 本保荐人及保荐代表人根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发 行上市保荐业务管理办法》、《上市公司证券发行注册管理办法》（以下简称"《注 册管理办法》"）等有关法律、行政法规和中国证券监督管理委员会、深圳证券 交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律 规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书中如无特别说明，相关用语与《海思科医药集团股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》中的含义相同。 3-3-1 海思科医药集团股份有限公司向特定对象发行 A 股股票申请文件 上市保荐书 公司是一家集新药研发、生产制造、推广营销业务于一体的多元化、专业化 医药集团，拥有覆盖麻醉、肠外营养、肿瘤止 ...

证券代码：002653 证券简称：海思科 公告编号：2025-083 海思科医药集团股份有限公司 关于 2025 年度向特定对象发行股票申请 获得深圳证券交易所受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 4 日晚间收到深圳证券交易所（以下简称"深交所"）出具的《关 于受理海思科医药集团股份有限公司向特定对象发行股票申请文件的 通知》（深证上审〔2025〕130 号）。深交所对公司报送的向特定对象 发行股票的申请文件进行了核对，认为申请文件齐备，决定予以受理。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得 中国证券监督管理委员会（以下简称"中国证监会"）同意注册后方 可实施，最终能否通过深交所审核并获得中国证监会作出同意注册的 决定及其时间尚存在不确定性。公司将根据该事项进展情况及时履行 信息披露义务，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 海思科医药集团股份有限公司董事会 2025 年 7 月 7 日 1 ...